Patents by Inventor David Horwitz

David Horwitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240042024
    Abstract: A novel nanoparticle platform has been developed that induces and expands multiple populations of suppressive regulatory cells in vivo for the prevention and treatment of immune-mediated disorders. These include autoimmune diseases, graft-versus-host disease, and transplant rejection. The regulatory cells expanded include both CD4+ and CD8+ T cells and NK cells. The nanoparticles function as artificial antigen-presenting cells (aAPC) that target T cells and NK cells and provide them the essential stimulation and cytokines they require for regulatory cell generation, function, and expansion. This is achieved without the use of the toxic immunosuppressive and biological agents now in use.
    Type: Application
    Filed: November 23, 2021
    Publication date: February 8, 2024
    Inventor: David A. HORWITZ
  • Publication number: 20150110738
    Abstract: The present invention is directed to generating suppressor cells by treating naive T cells with a suppressor-inducing composition such as anti-CD3, anti-CD28, IL-2, TGF-?, or some combination thereof. Such suppressor cells are administered to patients to prevent or treat immune disorders and are allogeneic to the patient.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 23, 2015
    Inventor: David Horwitz
  • Patent number: 8951796
    Abstract: The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: February 10, 2015
    Assignee: University of Southern California
    Inventors: Song Guo Zheng, David A. Horwitz, Juhua Wong
  • Publication number: 20130315939
    Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.
    Type: Application
    Filed: November 20, 2012
    Publication date: November 28, 2013
    Inventor: David Horwitz
  • Patent number: 8439837
    Abstract: The present invention is directed to a method of reducing false readings in a hypoglycemic detector that includes establishing a predetermined hypoglycemic threshold, a predetermined critical threshold, a predetermined rate of change in glucose concentration where the predetermined critical threshold is below the predetermined hypoglycemic threshold. A first sampling rate is then calculated based upon said predetermined hypoglycemic threshold, said predetermined critical threshold, and said predetermined rate of change in glucose concentration.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 14, 2013
    Assignee: LifeScan, Inc.
    Inventors: Sharbel E. Noujaim, David Horwitz, Manoj Sharma, Joseph Marhoul
  • Publication number: 20130084269
    Abstract: The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.
    Type: Application
    Filed: April 21, 2011
    Publication date: April 4, 2013
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA - USC STEVENS
    Inventors: Song Guo Zheng, David A. Horwitz, Juhua Wong
  • Publication number: 20100324401
    Abstract: The present invention relates to methods and systems for monitoring the effectiveness of diabetes treatment. Methods and systems in accordance with the present invention provide information relating to variability of glucose levels and hypoglycemia and hyperglycemia. Such information is based on time-stamped blood glucose data obtained from a meter or the like and actual measurements of HbA1c levels are not required.
    Type: Application
    Filed: August 10, 2010
    Publication date: December 23, 2010
    Inventors: Erik OTTO, David Horwitz, Kirk Harmon, Manoj Sharma
  • Patent number: 7824333
    Abstract: The present invention relates to methods and systems for monitoring the effectiveness of diabetes treatment. Methods and systems in accordance with the present invention provide information relating to variability of glucose levels and hypoglycemia and hyperglycemia. Such information is based on time-stamped blood glucose data obtained from a meter or the like and actual measurements of HbA1c levels are not required.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 2, 2010
    Assignee: LifeScan, Inc.
    Inventors: Erik Otto, David Horwitz, Kirk Harmon, Manoj Sharma
  • Publication number: 20100256047
    Abstract: A method for measuring and managing an analyte (e.g., blood glucose) in a bodily fluid includes storing a therapeutic administration protocol in a memory module of an analyte measurement and management device and measuring the analyte in the bodily fluid sample using an analyte measurement module of the device. The method also includes calculating, with a processor module of the device, a recommended therapeutic agent dosage (for example, an insulin dosage) and a recommended administration time for user-activated delivery of the dosage by employing the therapeutic administration protocol. The method further includes displaying the recommended therapeutic agent dosage and administration time to a user on a visual display of the device, delivering a therapeutic agent dosage to the user via a user-activated therapeutic agent delivery device, and detecting the user-activated administration of the therapeutic agent using a delivery device communication module of the device.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 7, 2010
    Applicant: LifeScan, Inc.
    Inventors: Zara Sieh, David Horwitz, David Price, Peter Krulevitch, Donna Savage, Robert Shartle
  • Patent number: 7799350
    Abstract: A method for inducing T cell tolerance in peripheral blood mononuclear cells (PBMCs) comprising adding a suppressive composition to said cells.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: September 21, 2010
    Assignee: University of Southern California
    Inventor: David A. Horwitz
  • Publication number: 20100221209
    Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.
    Type: Application
    Filed: October 29, 2009
    Publication date: September 2, 2010
    Inventor: David A. Horwitz
  • Publication number: 20100016700
    Abstract: Various embodiments of a diabetes management system are provided. One exemplary system may include an analyte measurement device and a therapeutic agent delivery device. The measurement device includes a measurement unit, display, and first wireless module. The therapeutic agent delivery device has a delivery device housing, delivery mechanism disposed in the housing that delivers a dosage of the agent to the user upon actuation by the user or health care provider, and a second wireless module. The second module, automatically, without prompting from a user or any active input or action by the user, transmits a signal to the first wireless module indicative of: (a) type of therapeutic agent delivered; and (b) amount of therapeutic agent delivered to the user; or (c) type of therapeutic agent device from which the therapeutic agent was administered. Also described are diabetes management devices and methods.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: LifeScan, Inc.
    Inventors: Zara Sieh, David Horwitz, David Price, Peter Krulevitch, Donna Savage, Robert Shartle
  • Publication number: 20100015112
    Abstract: The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity.
    Type: Application
    Filed: July 13, 2009
    Publication date: January 21, 2010
    Inventor: David A. Horwitz
  • Publication number: 20090257988
    Abstract: The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.
    Type: Application
    Filed: April 10, 2009
    Publication date: October 15, 2009
    Applicant: USC Stevens, Hughes Center
    Inventors: David A. Horwitz, J. Dixon Gray
  • Publication number: 20090075296
    Abstract: Methods and compositions for determining whether a T cell is a regulatory T cell and for determining whether a population of cells includes at least one regulatory T cell or a cell with the potential to become a regulatory T cell. The invention includes methods and compositions for detecting TGF-? on the surface of a cell. The invention also provides methods and compositions for evaluating the suppressive activity of a regulatory T cell based on the presence and/or the amount of membrane-bound TGF-?.
    Type: Application
    Filed: August 19, 2008
    Publication date: March 19, 2009
    Applicants: University of Southern California, National Institutes of Health
    Inventor: David A. Horwitz
  • Publication number: 20090061514
    Abstract: A method for inducing T cell tolerance in peripheral blood mononuclear cells (PBMCs) comprising adding a suppressive composition to said cells.
    Type: Application
    Filed: October 16, 2007
    Publication date: March 5, 2009
    Applicant: University of Southern California
    Inventor: David A. Horwitz
  • Publication number: 20080318313
    Abstract: The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation.
    Type: Application
    Filed: October 30, 2007
    Publication date: December 25, 2008
    Applicant: University of Southern California
    Inventor: David A. Horwitz
  • Publication number: 20080208026
    Abstract: The present invention is directed to a method of reducing false readings in a hypoglycemic detector that includes establishing a predetermined hypoglycemic threshold, a predetermined critical threshold, a predetermined rate of change in glucose concentration where the predetermined critical threshold is below the predetermined hypoglycemic threshold. A first sampling rate is then calculated based upon said predetermined hypoglycemic threshold, said predetermined critical threshold, and said predetermined rate of change in glucose concentration.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 28, 2008
    Applicant: LifeScan, Inc
    Inventors: Sharbel E. NOUJAIM, David Horwitz, Manoj Sharma, Joseph Marhoul
  • Publication number: 20080175823
    Abstract: The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 24, 2008
    Inventor: David A. Horwitz
  • Patent number: 7381563
    Abstract: The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patents that have received allogenic bone marrow transplants.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: June 3, 2008
    Assignee: University of Southern California
    Inventor: David A. Horwitz